+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hydroxycarbamide"

Thalassemia Drugs Global Market Report 2024 - Product Thumbnail Image

Thalassemia Drugs Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Sickle Cell Disease Treatment Global Market Report 2024 - Product Thumbnail Image

Sickle Cell Disease Treatment Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
From
From
Polycythemia Vera - Pipeline Insight, 2024 - Product Thumbnail Image

Polycythemia Vera - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Hypereosinophilic Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Hypereosinophilic Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
JAKAFI Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

JAKAFI Emerging Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
From
From
From
From
Polycythemia Vera - Epidemiology Forecast - 2032 - Product Thumbnail Image

Polycythemia Vera - Epidemiology Forecast - 2032

  • Report
  • February 2023
  • 94 Pages
  • Global
From
JAKAFI Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

JAKAFI Drug Insight and Market Forecast - 2032

  • Report
  • September 2022
  • 30 Pages
  • Global
From
From
Loading Indicator

Hydroxycarbamide is a drug used to treat chronic myeloid leukemia (CML). It is a type of chemotherapy drug that works by inhibiting the growth of cancer cells. It is also used to treat polycythemia vera, a rare blood disorder. Hydroxycarbamide is usually taken orally in tablet form, and is usually taken once or twice a day. It is also available in an injectable form. Common side effects of hydroxycarbamide include nausea, vomiting, diarrhea, and hair loss. Hydroxycarbamide is a relatively new drug, and is still in the process of being approved by regulatory bodies in different countries. It is currently approved in the United States, Canada, and the European Union. It is also approved in some other countries, such as Australia, New Zealand, and South Africa. Hydroxycarbamide is marketed by several pharmaceutical companies, including Novartis, Bristol-Myers Squibb, and Pfizer. Other companies that market hydroxycarbamide include Cipla, Teva Pharmaceuticals, and Mylan. Show Less Read more